PT-141
Bremelanotide
Description
PT-141, also known as bremelanotide, is a synthetic peptide derived from melanocyte-stimulating hormone. It is primarily recognized for its role in modulating sexual function and desire in both men and women.
Overview
PT-141, chemically known as bremelanotide, is a synthetic peptide that originated from research into naturally occurring melanocortin peptides. It is a derivative of alpha-melanocyte-stimulating hormone (α-MSH), a peptide involved in various physiological processes including skin pigmentation, appetite regulation, and sexual behavior. The development of PT-141 stemmed from observations in preclinical studies that α-MSH could induce sexual arousal. Bremelanotide received approval from the FDA in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This condition is characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing marked distress or interpersonal difficulty. The peptide is marketed under the brand name Vyleesi and is administered via a self-injection pen. Beyond its approved use in women, PT-141 has also been investigated for its potential to address sexual dysfunction in men, including erectile dysfunction (ED). Research indicates that it may be a viable option for men who do not respond to traditional ED medications like sildenafil. The mechanism by which PT-141 exerts its effects on sexual function involves its interaction with melanocortin receptors, specifically MC4R, which plays a crucial role in regulating sexual motivation and arousal. Its ability to stimulate sexual desire independently of direct sexual stimulation suggests a broad therapeutic potential for various sexual desire disorders.
Mechanism of Action
PT-141 functions as a melanocortin receptor agonist, particularly targeting MC4R in the central nervous system. This activation leads to an increase in dopamine release, which is associated with heightened sexual desire and arousal.
Benefits
- •Increases sexual desire in women with hypoactive sexual desire disorder (HSDD)
- •May improve erectile function in men unresponsive to sildenafil
- •Enhances sexual arousal
- •Promotes sexually satisfying events in women
Dosing Notes
For women with HSDD, the typical subcutaneous dose is 1.75 mg, administered approximately 45 minutes before anticipated sexual activity. Dosing should not exceed one administration per day and is limited to a maximum of eight doses per month. Some individuals experiencing adverse reactions may find efficacy with a reduced dose of 1.25 mg. In male research subjects, doses between 1 mg and 10 mg have been explored for erectile dysfunction, with some studies demonstrating significant erectile responses at doses exceeding 1 mg and dose-dependent improvements up to 20 mg.
Reported Side Effects
- •Nausea
- •Flushing
- •Injection site reactions
- •Headaches
- •Increased blood pressure
- •Vomiting
- •Arthralgia
- •Restless leg syndrome
- •Local hyperpigmentation
Safety Notes
Bremelanotide should be avoided by individuals who are pregnant, have cardiovascular disease, or uncontrollable hypertension due to the risk of temporary blood pressure elevation and heart rate reduction. In rare instances, it may lead to elevated serum enzyme levels and, even more rarely, acute liver damage.